Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma has re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajpai, Richa, Sharma, Aditi, Achreja, Abhinav, Edgar, Claudia L., Wei, Changyong, Siddiqa, Arusha A., Gupta, Vikas A., Matulis, Shannon M., McBrayer, Samuel K., Mittal, Anjali, Rupji, Manali, Barwick, Benjamin G., Lonial, Sagar, Nooka, Ajay K., Boise, Lawrence H., Nagrath, Deepak, Shanmugam, Mala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060223/
https://www.ncbi.nlm.nih.gov/pubmed/32144272
http://dx.doi.org/10.1038/s41467-020-15051-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060223/
https://www.ncbi.nlm.nih.gov/pubmed/32144272
http://dx.doi.org/10.1038/s41467-020-15051-z

Ejemplares similares